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The molecular basis of antibody 5E5, which recognizes the 
entire GalNAc unit as a primary epitope is disclosed. The 
antibody's contacts with the peptide are limited to mostly two 
residues, allowing it to show some degree of promiscuity. 
These findings open the door to the chemical design of 
peptide-mimetics for developing efficient anti-cancer vaccines 
and diagnostic tools. 
Mucins are heavily glycosylated proteins that play a key role in 
several biological processes. MUC1 is one of the most studied 
mucins.1 Although MUC1 exhibits complex O-glycans in healthy 
cells, in tumour tissues it is decorated with short carbohydrates. 
Consequently, different antigens that are masked in healthy 
cells, such as the Tn and STn antigens2,3 (GalNAc-D-1-O-Thr/Ser 
and Neu5Ac-D-(2-6)-GalNAc-D-1-O-Thr/Ser, respectively), are 
exposed in cancer cells and can trigger an immune response. 
These antigens are broadly expressed in many types of cancer 
and are well-accepted hallmarks of this disease.4,5 Despite the 
vast amount of clinical and immunological data available on 
antibodies that recognize aberrantly glycosylated MUC1, the 
molecular details by which these antibodies recognize their 
targets are scarce.6 This structural knowledge is fundamental to 
the development of new anti-MUC1 antibodies with improved 
specificities to advance cancer therapy.7 Also, to design new 
MUC1-inspired glycopeptides with enhanced binding strength 
and specificity for naturally occurring anti-MUC1 antibodies 
present in cancer patients to improve early cancer detection.8 
From a molecular recognition perspective, although most of 
anti-MUC1 monoclonal antibodies (mAb) recognize the peptide 
sequence DTRP, recent studies indicate that some bind to GSTAP 
or GVTS motifs.9–11 The unusual and incomplete glycosylation of 
MUC1 modulates the binding properties of these antibodies.7 In 
general, binding is enhanced by glycosylation of the PDTR 
epitope. In this respect, the X-ray structure of the complex 
between antibody AR20.5 and glycopeptide APDT*RP (in which 
T* = Tn-Thr = GalNAc-D-1-O-Thr) reveals that the contacts 
between the sugar and the antibody are negligible.6 However, 
the presence of the sugar improves glycopeptide binding 
because it stabilizes the conformation of the peptide that is 
recognized by the antibody. Similarly, SM3, recognizes mainly 
the peptide sequence and the sugar adopts a conformation that 
provides several additional stabilizing interactions with the 
antibody. 12 
To date, two high-resolution X-ray structure of a complex 
between an antibody and a glycopeptide, in which the 
carbohydrate is part of the epitope have been reported.13,14 
However, only one of these antibodies (named SN-101) refers to 
anti-MUC1 antibodies. SN-101 was designed specifically for this 
purpose following a smart strategy developed by Nishimura’s 
group.14 Yet, in this case, the GalNAc is not intimately recognized 
by the SN-101, and just GalNAc OH6 and OH4 are interacting 
with the antibody. 
The anti-MUC1 antibody 5E5 is an ideal candidate for detailed 
structural investigations since it recognizes mainly the sequence 
GSTAP and requires a GalNAc attached to the threonine residue. 
11 Besides, it has been successfully used to develop chimeric 
antigen receptor T cells (CAR-T cells).15 Notably, recent studies 
propose that 5E5 could recognize tumour cell lines that do not 
express MUC1-like glycopeptides, which suggests a certain 
degree of promiscuity.15,16 Initially, scFv-5E5 was cloned, 
expressed and purified to homogeneity to enable functional and 
structural characterization (ESI and Fig. S1). We evaluated then 
substrate specificity by isothermal titration calorimetry (ITC) 
measurements (Fig. 1A, S2-S3 and Table S1). According to these 
experiments, scFv-5E5 displays the highest affinity against 
glycopeptides 1 and the longer variant 1’, whereas it does not 
bind to unglycosylated derivative. We could not determine any 
binding of the antibody against GalNAc-D-1-O-Me, probably due 
to the very low affinity, as previously reported.11 Although the 
presence of two Tn antigens in the peptide (glycopeptide 3) 
modestly affects binding (Fig. 1), attachment of a sialic acid 
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moiety to the hydroxymethyl group of GalNAc (STn-containing 
glycopeptide 4) results in considerably weaker binding. This 
result is corroborated by the low signal-to-noise ratio observed 
in the recorded ITC profile and agrees with the preferences 
reported earlier.10 A similar result, in terms of affinity, was 
obtained when the glycopeptide 2 was tested. This clearly 
suggests that the antibody recognizes other regions of the 
tandem-repeat sequence of MUC1 and possibly other proteins 
as described before.16,17  
 
 
Fig. 1. (A) Glycopeptides synthesized and studied in this work. (B) ITC 
profiles for glycopeptide 3 titration with 20 µM scFv-5E5 solution at 25 
oC and pH = 7.5. (C) KD of glycopeptides 1, 1’ and 2-4 with scFv-5E5 
determined by ITC. (see also Table S1 and Fig. S2-S3).  
Further, we successfully obtained crystals of scFv-5E5 in a 
complex with compound 1 (Fig. 2, pdb ID: 6TNP). The resulting 
crystals allowed us to solve the structure at a resolution of 
3.00 Å and interpret the density map (Table S2 and Fig. S5). The 
glycopeptide lies within a surface groove formed by the light (L) 
and heavy (H) chains, and in particular is recognized by residues 
of the loops E3H-E4H, E9H-E10HE8L-E9L and E4H (Fig. 2). The 
GalNAc moiety is the most recognized part of the glycopeptide. 
Indeed, with exception of the OH6, all its hydroxyl groups are 
engaged in hydrogen bonds. In detail, hydroxyl group OH3 
interacts with the NH group of Ala33H and OH4 with the side 
chains of His32H and Ser99H. Equally, the endocyclic oxygen of 
the sugar is engaged in hydrogen bonding with Ser99H. The 
carbonyl group of GalNAc is involved in two hydrogen bonds 
with the side chain of His35H and Thr100H and the methyl group 
is engaged in a CH/π stacking interaction with His50H, which 
provides the impetus for the observed selectivity of 5E5 for 
GalNAc-containing antigens. The OH6 of the sugar is fully 
solvent-exposed, which explains why this antibody can also 
recognize STn-containing glycopeptides.10 The glycosidic linkage 
adopts the typical ‘eclipsed’ conformation,18,19 with I/\ values 
of 68.1o/151.0o. In contrast to the carbohydrate, the peptide 
moiety forms only one hydrogen bond with the protein. This 
stabilizing interaction involves the -CONH2 group in the C-
terminal region of the glycopeptide and the carbonyl group of 
Tyr98L. The N-terminal region (APGS) is completely exposed to 
the solvent and does not establish any contact with the 
antibody. The saturation-transfer difference (STD)-NMR 
spectrum obtained for 1 in presence of scFv-5E5 agrees with this 
epitope deduced from the X-ray structure (Fig. S6). This result is 
in striking contrast to that found for SN-101 antibody,14 in which 
a significant hydrogen bonding network is stablished between 
the antibody and the peptide. This feature presumably prevents 
its ability to recognize other peptide fragments. Notably, as in 
the case of SM3 mAb,12 the glycosylated Thr residue of the 
peptide adopts a helix-like conformation in the bound state. This 
conformer could be favoured by an intramolecular hydrogen 
bond between the NH of the contiguous Ala (Ala17) and the 
hydroxyl group of Ser15 (Fig. 2, dotted orange line), which in 
turn provides the proper shape complementarity with the 
antibody. 
 
Fig. 2. X-ray structure of glycopeptide 1 bound to scFv-5E5, showing the 
hydrogen bond interactions. PDB ID: 6TNP.  
Selectivity towards this peptide sequence (APGSTAP) is 
conferred by two CH-π stacking interactions that involve the 
methyl group of threonine and the five-membered ring of the C-
terminal proline with the aromatic moieties of Phe102H and 
Tyr100L, respectively. The importance of these two aromatic 
residues and those of His32H and His35H for the binding was 
confirmed by Ala substitutions by using site-directed 
mutagenesis (Table S1). Binding of mutants F102HA, H32HAH-
H35HA and Y100LA towards peptide 1 was severely impaired. 
Indeed, we could not detect clear binding for the first mutant, 
and a a1330- and a790-fold decrease in affinity was observed 
for H32HAH-H35HA and Y100LA mutants, respectively. A similar 
result was obtained when the C-terminal Pro of glycopeptide 1 
was replaced by an Ala residue (~400-fold decrease in binding, 
Table S1, Fig. S7-S8). We performed then a series of microarray 
experiments with synthetic mutations and glycoform 
substitutions. Glycopeptides obtained from solid phase peptide 
synthesis (SPPS) and microarray display were performed as 
previously described.20,21 Figure 3A shows that Ala mutation 
throughout a MUC1-like glycopeptide sequence completely 
abrogates 5E5 binding only when T* and Pro are mutated in the 








































































Journal Name  COMMUNICATION 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3  
Please do not adjust margins 
Please do not adjust margins 
GST*AP sequence, and reproduce previous work that used a 
random mutation library including Ala mutations at the GST*AP 
sequence.4 These results support that the minimal epitope is 
T*AP. Extended amino acid X substitutions at Ala position, 
further establish the true 5E5 epitope as -T*-X-P- (Figure 3B), 
which complements the crystal analysis and previous data.4 
Chemical synthesis also allowed us to conclude that extended 
glycoforms, such as cores Core-2 (C2), Core-3 (C3) and Core-4 
(C4), were not tolerated by the antibody (Figure 3C), which fits 
with hydrogen bonding requirements above commented. Thus, 
5E5 mAb probably interacts selectively with glycopeptides that 
comprise the -T*-X-P- motif, which is present in the MUC1 
tandem-repeat sequence but also in many other proteins. 
 
Fig. 3. (A) Microarray data for an Ala mutation walk through the entire 
20-mer MUC1-Tn glycopeptide. (B) Microarray data for the T-*-X-P 
mutations in the GST*AP region. (C) Microarray data for the additional 
glycoform isomers C2, C3 and C4.  
 
Putative 3D structures were then generated for the complexes 
formed between scFv-5E5 and glycopeptides 1, 1’ and 2-4, using 
the coordinates of the crystal structure of scFv-5E5/1. 0.5 µs 
Molecular Dynamics (MD) simulations were run for each 
complex to produce fully equilibrated structures in water (Fig. 4 
and S9-S19). It is important to note that in all simulated 
complexes the hydrogen bonds between GalNAc and the 
antibody observed in the X-ray structure are preserved (Fig. 
S18). With exception of complexes with derivatives 2 and 3, the 
N-terminal region of the peptide was rather flexible, owing to 
the lack of stabilizing contacts between the peptide and the 
antibody. Complex scFv-5E5/1 was stable through the complete 
simulation and both the hydrogen bonds and the CH-π stacking 
interactions present in the X-ray structure were highly 
populated. According to MD simulations, Pro19 and Ala20 of 
glycopeptide 1’ (APGSTAPP19A20HG) are engaged in CH/π 
interactions with Tyr38L and Tyr98L, respectively, which agrees 
with reported data4 (Fig. S10). In this case, we could not 
determine the epitope mapping by STD-NMR due to the 
overlapping of key signals (Fig. S6). Presumably, the shorter 
peptide backbone of 1 related to 1’ and the subsequent 
reduction in the entropic penalty associated with the binding 
process could compensate for these additional stabilizing 
interactions displayed by 1’, as indicated by the KD values 
determined by ITC assays. The additional glycosylation of 
derivative 1 with GalNAc, which renders diglycopeptide 3, has 
two significant consequences in the bound state: (a) it rigidifies 
the N-terminal moiety of the peptide; and (b) the Ser residue is 
forced to adopt a helix-like conformation, which is low 
populated in solution.22 The entropy penalty associated to 
binding, as confirmed by the ITC experiment (Table S1), could be 
counterbalanced by extra contacts between the GalNAc linked 
to Ser and 5E5, which explains the modest decrease of binding 
for this diglycopeptide. In case of complex scFv-5E5/4, the MD 
simulations indicate that the Neu5Ac unit impairs the 
recognition of the peptide fragment. After 120 ns, the CH-π 
stacking interaction between the C-terminal Pro and Tyr100L is 
significantly attenuated due to the increasing distance between 
these residues (Fig. S19). This feature may explain why 
glycopeptide 4 binds worse than derivative 1 to the antibody.  
 
Fig. 4. (A) Overlay of 10 frames of scFv-5E5/3 complex sampled from 0.5 
µs MD simulations. RMSD value (± S.D.) of the peptide backbone is 
shown. (B) MST binding curve used to determine KD for the complete 
5E5 with glycopeptide MUC1-Tn16. Error represents SD between two 
separate experiments; KD values ± SD are shown. (C) Section of the 300 
ms 2D-NOESY spectrum (600 MHz) in H2O/D2O (9:1) at 275 K and pH 5.5 
for MUC1-Tn16. (D) Structural ensembles derived from 200 ns 
experiment-guided MD simulations for MUC1-Tn16 in water. The RMSD 
value (± S.D.) of heavy atoms is shown. (E) Superposition of the 
APGST*AP fragment of MUC1-Tn16 conformers found in solution with 
the conformation of glycopeptide 1 obtained from the X-ray structure of 
scFv-5E5/1. 
 
In the scFv-5E5/2 complex, the Asp residue is forced to adopt a 
helix-like conformation to favour the shape complementarity in 
the binding site. Taking into account the extended disposition 
adopted by this glycopeptide in solution,7,12,23 this 
conformational change in the 5E5-bound state can explain the 
entropy cost associated to the binding and, consequently, the 
lower affinity of scFv-5E5 towards glycopeptide 2. We also 
performed MD simulations of glycopeptide APGSS*AP (1-Ser, 
Fig. S20), in which the Thr residue was replaced by Ser, bound to 
scFv-5E5. The CH-π stacking interactions that involve F102H and 
Y100L are harmed at the beginning of the simulation and only 
the stabilizing interactions between GalNAc and the antibody 
are preserved. This outcome implies that 5E5 would only 
recognize proteins containing the motif -T*-X-P. This also agrees 
with our previous data where TS(GalNAc)AP-motif within MUC1 
tandem repeat did not serve as a ligand for 5E5.20 We performed 
then a conformational analysis of glycopeptide MUC1-Tn16 (Fig. 
4B). MUC1-Tn16 is recognized by scFv-5E5 and complete 
antibody 5E5 with KD values of 3.42 and 2.59 µM, respectively 
(Fig. 4B and S4). The analysis of the NMR spectra for this 
compound (Table S3, Fig. 4C, S21 and S22), allowed us to obtain 
68 NMR-derived distances (Table S4) that were used as 
restraints in experiment-guided MD simulations (ESI). The 
peptide backbone is rather flexible in water, particularly for 
those amino acids at distal positions from the glycosylation point 
and the GalNAc moiety forces the underlying threonine to adopt 
and extended conformation, in line with previous studies (Fig. 
4D, 4E, S23).23,24 Thus, as the SM3 antibody, 5E5 selects a 
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conformer poorly populated in solution. This result contrasts to 
that found for SN-101, for which the structure of the 
glycopeptide in bound state is identical to its solution NMR-
derived structure. In conclusion, we have solved the crystal 
structure of the antitumoral antibody 5E5 in complex with its 
natural epitope. Our findings establish that the main driving 
force of 5E5 mAb binding is the recognition of the GalNAc 
moiety and to a lesser extent the Thr residue and the 
neighbouring downstream proline residue. 5E5 tolerates well 
any amino acid at APGST*XP, as well as any single mutation in 
the tandem repeat sequence not located in the epitope and 
recognizes a conformer low populated in solution. This can be 
useful in designing novel antigens to formulate new anticancer 
vaccines and develop novel kits for cancer detections. Funding 
from the Spanish MCIU (RTI-2018-099592-B-C21, CTQ2013-
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